Payment overview · 2025
General Payments
$28.96
2 reported records · 2 companies
Healthcare provider profile · identity verified
Michael E Hodges, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · MOUNTAIN HOME, AR · NPI 1679547608
Verified facts
What the public records show
CMS Open Payments records show Michael E Hodges, M.D. received $28.96 in general payments during 2025 across 2 reported records.
Amgen Inc. accounted for 51.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 4 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 206 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Amgen Inc. | Unresolved — no canonical attribution shown | $14.98 | 51.7% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $13.98 | 48.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $28.96 | 2 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $14.98 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $14.98 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $13.98 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $13.98 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 206 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
206 | 46 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 1006 | 253 |
| Atorvastatin Calcium | Atorvastatin Calcium | 885 | 243 |
| Lisinopril | Lisinopril | 701 | 192 |
| Amlodipine Besylate | Amlodipine Besylate | 634 | 173 |
| Metformin Hcl | Metformin Hcl | 474 | 127 |
| Pantoprazole Sodium | Pantoprazole Sodium | 403 | 126 |
| Losartan Potassium | Losartan Potassium | 397 | 113 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 361 | 104 |
| Hydrochlorothiazide | Hydrochlorothiazide | 322 | 91 |
| Metoprolol Tartrate | Metoprolol Tartrate | 292 | 90 |
| Simvastatin | Simvastatin | 292 | 80 |
| Gabapentin | Gabapentin | 274 | 86 |
| Omeprazole | Omeprazole | 264 | 76 |
| Atenolol | Atenolol | 240 | 64 |
| Alprazolam | Alprazolam | 238 | 55 |
| Glimepiride | Glimepiride | 238 | 66 |
| Clopidogrel | Clopidogrel Bisulfate | 237 | 64 |
| Alendronate Sodium | Alendronate Sodium | 224 | 51 |
| Sertraline Hcl | Sertraline Hcl | 213 | 55 |
| Meloxicam | Meloxicam | 207 | 59 |
| Eliquis | Apixaban | 206 | 46 |
| Tamsulosin Hcl | Tamsulosin Hcl | 197 | 55 |
| Metoprolol Succinate | Metoprolol Succinate | 191 | 55 |
| Fluoxetine Hcl | Fluoxetine Hcl | 188 | 53 |
| Furosemide | Furosemide | 180 | 62 |
| Carvedilol | Carvedilol | 165 | 40 |
| Citalopram Hbr | Citalopram Hydrobromide | 152 | 49 |
| Trazodone Hcl | Trazodone Hcl | 152 | 43 |
| Potassium Chloride | Potassium Chloride | 144 | 41 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 142 | 23 |
| Warfarin Sodium | Warfarin Sodium | 127 | 31 |
| Zolpidem Tartrate | Zolpidem Tartrate | 126 | 21 |
| Allopurinol | Allopurinol | 123 | 34 |
| Ozempic | Semaglutide | 122 | 18 |
| Tramadol Hcl | Tramadol Hcl | 121 | 44 |
| Tizanidine Hcl | Tizanidine Hcl | 116 | 37 |
| Pravastatin Sodium | Pravastatin Sodium | 115 | 31 |
| Escitalopram Oxalate | Escitalopram Oxalate | 112 | 33 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 111 | 42 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 109 | 30 |
| Famotidine | Famotidine | 101 | 33 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 92 | 26 |
| Duloxetine Hcl | Duloxetine Hcl | 91 | 29 |
| Donepezil Hcl | Donepezil Hcl | 85 | 26 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 81 | 13 |
| Synthroid | Levothyroxine Sodium | 80 | 24 |
| Lorazepam | Lorazepam | 79 | 16 |
| Prednisone | Prednisone | 73 | 41 |
| Finasteride | Finasteride | 72 | 21 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 70 | 65 |
| Hydralazine Hcl | Hydralazine Hcl | 70 | 19 |
| Quetiapine Fumarate | Quetiapine Fumarate | 65 | 12 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 64 | 17 |
| Montelukast Sodium | Montelukast Sodium | 63 | 19 |
| Spironolactone | Spironolactone | 63 | 17 |
| Bupropion Xl | Bupropion Hcl | 62 | 13 |
| Fluticasone Propionate | Fluticasone Propionate | 59 | 17 |
| Mirtazapine | Mirtazapine | 57 | 16 |
| Oxybutynin Chloride | Oxybutynin Chloride | 55 | 22 |
| Diazepam | Diazepam | 54 | 15 |
| Nifedipine Er | Nifedipine | 53 | 15 |
| Paroxetine Hcl | Paroxetine Hcl | 53 | 11 |
| Clonazepam | Clonazepam | 52 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 51 | 18 |
| Farxiga | Dapagliflozin Propanediol | 47 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 46 | 11 |
| Propranolol Hcl | Propranolol Hcl | 43 | 14 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 41 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 38 | 22 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 38 | 13 |
| Ezetimibe | Ezetimibe | 38 | 11 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 38 | suppressed |
| Xarelto | Rivaroxaban | 37 | suppressed |
| Temazepam | Temazepam | 36 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 35 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 35 | 22 |
| Methylprednisolone | Methylprednisolone | 35 | 32 |
| Pregabalin | Pregabalin | 35 | 12 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 35 | 29 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 35 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 32 | 24 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 32 | suppressed |
| Cefdinir | Cefdinir | 31 | 29 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 31 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 30 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 30 | 11 |
| Diclofenac Sodium | Diclofenac Sodium | 30 | suppressed |
| Lovastatin | Lovastatin | 30 | suppressed |
| Memantine Hcl | Memantine Hcl | 30 | suppressed |
| Acyclovir | Acyclovir | 29 | 14 |
| Bumetanide | Bumetanide | 29 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 29 | suppressed |
| Estradiol | Estradiol | 29 | 11 |
| Ondansetron Hcl | Ondansetron Hcl | 29 | suppressed |
| Gemfibrozil | Gemfibrozil | 28 | suppressed |
| Amoxicillin | Amoxicillin | 27 | 22 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 27 | suppressed |
| Myrbetriq | Mirabegron | 27 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 26 | suppressed |
| Levetiracetam | Levetiracetam | 26 | suppressed |
| Ondansetron Odt | Ondansetron | 26 | 13 |
| Primidone | Primidone | 26 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 26 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 25 | 18 |
| Nystatin | Nystatin | 25 | 13 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 25 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 25 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 25 | suppressed |
| Celecoxib | Celecoxib | 24 | suppressed |
| Fluconazole | Fluconazole | 24 | 13 |
| Naproxen | Naproxen | 24 | suppressed |
| Ramipril | Ramipril | 24 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 23 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 23 | suppressed |
| Nitroglycerin | Nitroglycerin | 23 | 18 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 23 | 16 |
| Bupropion Hcl Sr | Bupropion Hcl | 22 | suppressed |
| Methotrexate | Methotrexate Sodium | 22 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 22 | suppressed |
| Risperidone | Risperidone | 22 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 21 | suppressed |
| Dutasteride | Dutasteride | 21 | suppressed |
| Glipizide | Glipizide | 21 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 21 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 21 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 20 | suppressed |
| Digoxin | Digoxin | 20 | suppressed |
| Lansoprazole | Lansoprazole | 20 | suppressed |
| Novolog Flexpen | Insulin Aspart | 20 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 20 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 19 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 19 | suppressed |
| Januvia | Sitagliptin Phosphate | 19 | suppressed |
| Jardiance | Empagliflozin | 19 | suppressed |
| Fenofibrate | Fenofibrate | 18 | suppressed |
| Gemtesa | Vibegron | 18 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 17 | 17 |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 17 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 17 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 17 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 16 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Novolin N | Insulin Nph Human Isophane | 16 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 15 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 15 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 15 | suppressed |
| Ibuprofen | Ibuprofen | 14 | suppressed |
| Mesalamine Dr | Mesalamine | 14 | suppressed |
| Topiramate | Topiramate | 14 | suppressed |
| Azithromycin | Azithromycin | 13 | 12 |
| Diltiazem 24hr Er | Diltiazem Hcl | 13 | suppressed |
| Levemir | Insulin Detemir | 13 | suppressed |
| Abilify Maintena | Aripiprazole | 12 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 12 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 12 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Eplerenone | Eplerenone | 12 | suppressed |
| Irbesartan | Irbesartan | 12 | suppressed |
| Ketoconazole | Ketoconazole | 12 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 12 | suppressed |
| Metronidazole | Metronidazole | 12 | suppressed |
| Nabumetone | Nabumetone | 12 | suppressed |
| Novolog | Insulin Aspart | 12 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 12 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 12 | suppressed |
| Trueplus Insulin Syringe | Syringe-Needle,insulin,0.5 Ml | 12 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 11 | suppressed |
| Desipramine Hcl | Desipramine Hcl | 11 | suppressed |
| Entresto | Sacubitril/Valsartan | 11 | suppressed |
| Eszopiclone | Eszopiclone | 11 | suppressed |
| Levemir Flexpen | Insulin Detemir | 11 | suppressed |
| Migergot | Ergotamine Tartrate/Caffeine | 11 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 11 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $28.96 · 2 records | Amgen Inc. | ELIQUIS, NURTEC ODT, OTEZLA, REPATHA | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with PFIZER INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error